FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washi

Washington, D.C. 20549	OMB APPROVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-	

OMB Number: 3235									
Estimated average burden									
hours per response:	0.1								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					0, 0	COMO	11 00(11) 0		invesiment	. 501	inpurity Act	01 1040							
1. Name and Address of Reporting Person* Dolecek Gayle R				2. Issuer Name and Ticker or Trading Symbol Sucampo Pharmaceuticals, Inc. [SCMP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Dolecek Gayle K						_								X Direct	or		10% Ov	vner	
(Last) (First) (Middle)					Date of Earliest Transaction (Month/Day/Year)								_	X Office below	r (give title)		Other (s below)	specify	
4520 EAST-WEST HWY					01/15/2010									VP of Research & Development					
																	•		
SUITE 300													-						
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
BETHES	SDA M	D	20814											X Form	filed by One	e Repo	orting Perso	n	
														Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transact Date (Month/Day	Execution Date,			3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) (5) (8)				Benefici Owned I	es For ially (D) Following (I)		orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
						Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	ate, Transa Code (I				Expiration (Month/Day ed				7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Ownersl Form: Direct (I or Indire (I) (Instr.	Ownership	Beneficial Ownership ct (Instr. 4)	
				Co	de V	,	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (Right to buy)	\$3.85	01/15/2010		A			35,000		(1)	(01/15/2020	Class A common stock	35,000	\$0.00	35,00	0	D		

Explanation of Responses:

1. The option is vested as to 8,750 shares immediately, with the remaining shares vesting in three equal installments of 8,750 each on the first, second and third anniversaries of the grant date.

Remarks:

/s/ Gayle R. Dolecek 01/26/2010 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.